CMND Jumped 84% on Positive CMND-100 Trial Data — RTPR Had the Wire in 53ms
CMND jumped 84% after positive CMND-100 safety results. RTPR delivered the GlobeNewswire release in 53ms at $0.83 before the run to $1.53.
Clearmind Medicine (NASDAQ: CMND) jumped 84% on April 20, 2026 after announcing positive top-line safety results for its psychedelic treatment CMND-100. When RTPR delivered the GlobeNewswire release, CMND was trading at $0.83—the entry point available to subscribers who saw the wire first.
What the Press Release Said
The press release announced that CMND-100, Clearmind's proprietary psychedelic treatment for Alcohol Use Disorder (AUD), met its primary endpoint in the clinical trial. The company reported positive top-line safety results, a critical milestone for any biotech advancing a novel compound through the FDA pathway.
For a small-cap biotech pursuing psychedelic medicine—a therapeutic area with significant regulatory scrutiny—meeting the primary safety endpoint removes a major hurdle. AUD represents a substantial market opportunity, and CMND-100 reaching this milestone validates the treatment's safety profile for potential future efficacy trials.
Why the Stock Moved
Binary catalysts in biotech produce violent moves. Trial results either meet endpoints or they don't. There's no middle ground, and the market prices in the outcome within seconds of the news hitting.
CMND was trading at $0.83 when the wire crossed. The stock ran to a peak of $1.53 as traders reacted to the positive headline. That's an 84% gain from wire to peak—the kind of move that defines a trading session.
Small-cap biotechs with positive trial data attract momentum traders immediately. The combination of a met primary endpoint, a novel therapeutic approach in psychedelics, and a liquid NASDAQ listing created the conditions for a fast, aggressive move higher.
RTPR Speed: This GlobeNewswire release was delivered to RTPR subscribers in 53ms. At that moment, CMND was trading at $0.83. The stock peaked at $1.53. Free news aggregators typically lag 2–4 minutes behind the wire services—by then, much of the initial move has already occurred.
The Binary Nature of PDUFA and Trial Events
Biotech traders understand that trial readouts are all-or-nothing events. A positive safety result like this one doesn't guarantee approval, but it keeps the program alive and advancing. A failure would have sent the stock in the opposite direction just as quickly.
The speed advantage matters most in these moments. When the headline confirms the outcome, the first traders to see it can act at prices like $0.83 before the move accelerates. By the time the news reaches mainstream financial media, the chart already tells the story.
Want This Speed?
RTPR delivered this GlobeNewswire release in 53ms, while CMND was still trading at $0.83. The stock ran to $1.53.
If you trade biotech catalysts, earnings, or contract wins, wire speed determines your entry point. See pricing at rtpr.io/pricing or review the API documentation at rtpr.io/docs.